## Mi-Ok Kim

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6086250/publications.pdf

Version: 2024-02-01

117625 4,807 82 34 citations papers

67 h-index g-index 86 86 86 7497 docs citations times ranked citing authors all docs

98798

#	Article	IF	Citations
1	Synthesizing external aggregated information in the presence of population heterogeneity: A penalized empirical likelihood approach. Biometrics, 2022, 78, 679-690.	1.4	12
2	Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace) Tj ETQq0 0	0 n <b>g:B</b> T/O	verkock 10 Tf 5
3	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	10.7	148
4	Randomized controlled trial of early, small-volume formula supplementation among newborns: A study protocol. PLoS ONE, 2022, 17, e0263129.	2.5	4
5	Effect of Social Needs Case Management on Hospital Use Among Adult Medicaid Beneficiaries. Annals of Internal Medicine, 2022, 175, 1109-1117.	3.9	14
6	MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene, 2021, 40, 951-963.	5.9	12
7	Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection. Computational Statistics and Data Analysis, 2021, 158, 107167.	1.2	4
8	Synthesizing external aggregated information in the penalized Cox regression under population heterogeneity. Statistics in Medicine, 2021, 40, 4915-4930.	1.6	3
9	Perioperative Normal Saline Administration and Delayed Graft Function in Patients Undergoing Kidney Transplantation: A Retrospective Cohort Study. Anesthesiology, 2021, 135, 621-632.	2.5	11
10	PDâ€L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head and Neck, 2021, 43, 3364-3373.	2.0	7
11	Predictive generalized varyingâ€coefficient longitudinal model. Statistics in Medicine, 2021, 40, 6243-6259.	1.6	2
12	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	8.2	20
13	Dynamic Risk Prediction for Hospital-Acquired Pressure Injury in Adult Critical Care Patients., 2021, 3, e0580.		4
14	Propensity score analysis for correlated subgroup effects. Statistical Methods in Medical Research, 2020, 29, 1067-1080.	1.5	1
15	Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control. Pharmaceutical Statistics, 2020, 19, 613-625.	1.3	5
16	Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discovery, 2019, 9, 46-63.	9.4	245
17	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i> -altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	8.5	46
18	Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1799-1806.	4.4	14

#	Article	IF	Citations
19	RUNX represses <i>Pmp22</i> to drive neurofibromagenesis. Science Advances, 2019, 5, eaau8389.	10.3	11
20	Variation in Care in the Management of Children With Crohn's Disease: Data From a Multicenter Inception Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 1208-1217.	1.9	20
21	STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene, 2019, 38, 2876-2884.	5.9	44
22	Age-of-diagnosis dependent ileal immune intensification and reduced alpha-defensin in older versus younger pediatric Crohn Disease patients despite already established dysbiosis. Mucosal Immunology, 2019, 12, 491-502.	6.0	18
23	Estimating heterogeneous treatment effects for latent subgroups in observational studies. Statistics in Medicine, 2019, 38, 339-353.	1.6	3
24	Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCl Insight, 2019, 4, .	5.0	21
25	Familial Association of Granulocyteâ€Macrophage Colonyâ€Stimulating Factor Autoantibodies in Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 767-772.	1.8	3
26	Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles. Inflammatory Bowel Diseases, 2018, 24, 2285-2290.	1.9	15
27	Bayesian selective responseâ€adaptive design using the historical control. Statistics in Medicine, 2018, 37, 3709-3722.	1.6	8
28	COMPARISON OF EXTENDED EMPIRICAL LIKELIHOOD METHODS: SIZE AND SHAPE OF TEST BASED CONFIDENCE REGIONS. Statistica Sinica, $2018$ , , .	0.3	0
29	Multiple quantile regression analysis of longitudinal data: Heteroscedasticity and efficient estimation. Journal of Multivariate Analysis, 2017, 155, 334-343.	1.0	4
30	Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet, The, 2017, 389, 1710-1718.	13.7	482
31	Fertility preservation with ovarian stimulation and time to treatment in women with stage Il–III breast cancer receiving neoadjuvant therapy. Breast Cancer Research and Treatment, 2017, 165, 151-159.	2.5	47
32	Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease. Nature Genetics, 2017, 49, 1517-1521.	21.4	146
33	Graft survival of pediatric kidney transplant recipients selected for de novo steroid avoidance—a propensity score-matched study. Nephrology Dialysis Transplantation, 2017, 32, 1424-1431.	0.7	13
34	Randomâ€effects metaâ€analysis for systematic reviews of phase I clinical trials: Rare events and missing data. Research Synthesis Methods, 2017, 8, 124-135.	8.7	4
35	A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatric Blood and Cancer, 2017, 64, e26258.	1.5	12
36	Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 715-722.	1.8	39

#	Article	IF	CITATIONS
37	Insertional Mutagenesis Identifies a STAT3/Arid $1b\hat{l}^2$ -catenin Pathway Driving Neurofibroma Initiation. Cell Reports, 2016, 14, 1979-1990.	6.4	55
38	Efficient quantile marginal regression for longitudinal data with dropouts. Biostatistics, 2016, 17, 561-575.	1.5	11
39	Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatric Blood and Cancer, 2015, 62, 1709-1716.	1.5	59
40	Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. Statistics in Medicine, 2014, 33, 4029-4042.	1.6	8
41	Oxandrolone for the treatment of bone marrow failure in Fanconi anemia. Pediatric Blood and Cancer, 2014, 61, 11-19.	1.5	31
42	Utility of Neutrophil Fc $\hat{l}^3$ Receptor I (CD64) Index as a Biomarker for Mucosal Inflammation in Pediatric Crohn $\hat{E}$ 1/4s Disease. Inflammatory Bowel Diseases, 2014, 20, 1.	1.9	24
43	Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology, 2014, 146, 383-391.	1.3	224
44	Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. Journal of Clinical Investigation, 2014, 124, 3617-3633.	8.2	431
45	An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis. Biology of Blood and Marrow Transplantation, 2013, 19, 1625-1631.	2.0	65
46	Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathologica, 2013, 125, 159-168.	7.7	104
47	A Highâ€Resolution Analysis of Process Improvement: Use of Quantile Regression for Wait Time. Health Services Research, 2013, 48, 333-347.	2.0	9
48	Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Annals of Neurology, 2013, 74, 679-687.	5.3	332
49	Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood, 2013, 121, 877-883.	1.4	132
50	Increased Prevalence of Luminal Narrowing and Stricturing Identified by Enterography in Pediatric Crohn's Disease Patients With Elevated Granulocyteâ€"Macrophage Colony Stimulating Factor Autoantibodies. Inflammatory Bowel Diseases, 2013, 19, 2146-2154.	1.9	11
51	Granulocyte–Macrophage Colony-Stimulating Factor Autoantibodies. Inflammatory Bowel Diseases, 2013, 19, 1671-1680.	1.9	64
52	MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Journal of Clinical Investigation, 2013, 123, 340-347.	8.2	273
53	The Fanconi Anemia Pathway Limits Human Papillomavirus Replication. Journal of Virology, 2012, 86, 8131-8138.	3.4	53
54	Improved outcomes for stem cell transplant recipients requiring pediatric intensive care. Pediatric Critical Care Medicine, 2012, 13, e336-e342.	0.5	71

#	Article	IF	Citations
55	Claus Thorn Ekstrom and Helle Sorensen: Statistical Data Analysis for the Life Sciences. Journal of Agricultural, Biological, and Environmental Statistics, 2012, 17, 702-703.	1.4	O
56	Preclincial testing of Sorafenib and RAD001 in the <i>Nf</i> <sup><i>flox/flox</i></sup> <i>;DhhCre</i> mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatric Blood and Cancer, 2012, 58, 173-180.	1.5	60
57	Empirical likelihood analysis for the heteroscedastic accelerated failure time model. Statistica Sinica, 2012, 22, .	0.3	11
58	Censored quantile regression for residual lifetimes. Lifetime Data Analysis, 2012, 18, 177-194.	0.9	13
59	Semiparametric Approach to a Random Effects Quantile Regression Model. Journal of the American Statistical Association, 2011, 106, 1405-1417.	3.1	41
60	Granulocyte Macrophageâ€Colonyâ€stimulating Factor Autoantibodies and Increased Intestinal Permeability in Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 542-548.	1.8	33
61	The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatric Blood and Cancer, 2011, 57, 648-653.	1.5	19
62	Biomarkers for early detection of sickle nephropathy. American Journal of Hematology, 2011, 86, 559-566.	4.1	60
63	Semiparametric Approach to a Random Effects Quantile Regression Model. Journal of the American Statistical Association, 2011, 106, 1405-1417.	3.1	7
64	Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood, 2010, 116, 5824-5831.	1.4	241
65	Improved recipient survival with maternal nifedipine in twin-twin transfusion syndrome complicated by TTTS cardiomyopathy undergoing selective fetoscopic laser photocoagulation. American Journal of Obstetrics and Gynecology, 2010, 203, 397.e1-397.e9.	1.3	13
66	The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis, 2010, 31, 886-893.	2.8	57
67	A Randomized Controlled Trial of Growth Hormone in Active Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 130-139.	1.8	46
68	Statistical Issues in Longitudinal Data Analysis for Treatment Efficacy Studies in the Biomedical Sciences. Molecular Therapy, 2010, 18, 1724-1730.	8.2	64
69	Numerical chromosomal changes and risk of development of myelodysplastic syndrome–acute myeloid leukemia in patients with Fanconi anemia. Cancer Genetics and Cytogenetics, 2010, 203, 180-186.	1.0	53
70	Mammary gland differentiation by early life exposure to enantiomers of the soy isoflavone metabolite equol. Food and Chemical Toxicology, 2010, 48, 3042-3050.	3.6	23
71	Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome Blood, 2010, 116, 1680-1680.	1.4	0
72	Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clinical Immunology, 2009, 132, 116-123.	3.2	51

#	Article	IF	CITATIONS
73	Combined multiple testing by censored empirical likelihood. Journal of Statistical Planning and Inference, 2009, 139, 814-827.	0.6	11
74	Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Murine Ileitis and Progressive Ileal Crohn's Disease. Gastroenterology, 2009, 136, 1261-1271.e3.	1.3	101
75	Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor- $\hat{l}\pm$ on Fanconi anemia hematopoietic stem and progenitor cells. Blood, 2009, 113, 5111-5120.	1.4	25
76	Empirical likelihood for linear models in the presence of nuisance parameters. Statistics and Probability Letters, 2008, 78, 1445-1451.	0.7	1
77	Evaluation of orthodontic mini-implant anchorage in premolar extraction therapy in adolescents. American Journal of Orthodontics and Dentofacial Orthopedics, 2008, 133, 642-653.	1.7	86
78	Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Molecular Cancer Therapeutics, 2008, 7, 1237-1245.	4.1	130
79	Rapid Lentiviral Transduction Preserves the Engraftment Potential of Fancaâ $^{\circ}$ /â $^{\circ}$ Hematopoietic Stem Cells. Molecular Therapy, 2008, 16, 1154-1160.	8.2	38
80	Quantile regression with varying coefficients. Annals of Statistics, 2007, 35, 92.	2.6	153
81	Small pituitary size in children with Fanconi Anemia. Pediatric Blood and Cancer, 2007, 49, 166-170.	1.5	22
82	On marginal estimation in a semiparametric model for longitudinal data with time-independent covariates. Metrika, 2002, 55, 67-74.	0.8	4